Examination of saliva and Blood components substances in patient with gum diseases along with heart disease

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

Inclusion criteria for healthy individuals:

Based on the classification system introduced by Kornman and Tonetti et al, 2018.

1. Pristine periodontal health:

· No bleeding on probing.

· Normal gingival sulcus depth.

· Normal bone heights.

· Controlled modifying factors.

· Controlled predisposing factors.

2.Clinical periodontal health (intact periodontium):

· No or minimal bleeding on probing.

· Normal gingival sulcus depth.

· Normal bone heights.

· Controlled modifying factors.

· Controlled predisposing factors.

IInclusion criteria for Stage III/IV Periodontitis:

Based on the classification system introduced by Kornman and Tonetti et al, 2018.

1.Stage III:

•Interdental clinical attachment loss at site of greatest loss = 5mm.

•Radiographic bone loss extending to middle or apical third of root

•Tooth loss due to periodontitis = 4 teeth.

•Probing depth = 6mm.

•Extent: Greater than 30% of teeth involved (Generalized)

2.Stage IV:

•Interdental clinical attachment loss at site of greatest loss = 5mm.

•Radiographic bone loss extending to middle or apical third of root

•Tooth loss due to periodontitis = 5 teeth.

•Extent: Greater than 30% of teeth involved (Generalized)

Atherosclerosis in this study is defined as an event of Acute Myocardial Infarction, Acute coronary syndrome, patients with defined coronary artery disease (Coronary angiography) and patients post bypass and post stenting. Patients with aortic aneurysms (pathogenesis –atherosclerosis)

Inclusion criteria for cardiovascular patients:

1.History of angina and not consuming lipid lowering drugs(statins)

2.Borderline high to high lipid profile inclusive of total cholesterol, Triglycerides and LDL (As per NCEP-ATP III classification)

a. Total cholesterol level above 200 mg/dL

b. Triglycerides above 150 mg/dL

c.HDL above 60 mg/dL

d.LDL above 130mg/dL

Exclusion Criteria

1.Patients with immunodeficiency disorders.

2.Patients with other systemic inflammatory conditions like sepsis, pneumonia, pleural effusion, intra-abdominal infections, inflammatory bowel disorders, inflammatory rheumatoid disorders, chronic kidney disease, Diabetes, cancers, COPD, asthma, HIV and hepatitis will be excluded from the study.

3.History of periodontal treatment within the last 6 months.

4.History of antibiotic therapy in the past 3 months.

5.Subjects who are not willing to participate in the study.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To correlate the ability of Mitofusin-1 and Mitofusin-2 as a potential common Serum and Salivary biomarker for stage III/IV Periodontitis and risk of developing Atherosclerotic cardiovascular disease <br/ ><br>Timepoint: Baseline <br/ ><br>

Secondary Outcome Measures